Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 18/20 | 0.78 |
| ▸ | AR | P10275 | 5/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175883 | 0.88 | PGR (1.00) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4170374 | 0.86 | PGR (0.71) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4175155 | 0.82 | PGR (0.82) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4178875 | 0.81 | PGR (0.81) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4180155 | 0.80 | PGR (1.00) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL27512075 | 0.80 | KDM4E (0.63) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4183779 | 0.79 | PGR (1.00) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4189943 | 0.78 | PGR (1.00) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL16812765 | 0.75 | PGR (0.70) | PGRARKDM4EMAPTALDH1A1 | |
| SCHEMBL4179561 | 0.74 | PGR (0.69) | PGRARKDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1172917-C | Steroid receptor modulator compounds and methods | ��λ��ҩ��ɷ�����˾ | 2004-10-27 | — | — | CN | claimed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | claimed |
| EP-1043315-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-11 | — | — | EP | claimed |
| CN-1175247-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 1998-03-04 | — | — | CN | claimed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | claimed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
| CN-1626534-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2005-06-15 | — | — | CN | disclosed |
| CN-1172917-C | Steroid receptor modulator compounds and methods | ��λ��ҩ��ɷ�����˾ | 2004-10-27 | — | — | CN | disclosed |
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| EP-1043325-B1 | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2004-06-16 | — | — | EP | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1041071-A1 | Methods for the preparation of coumarine derivatives | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6121450-A | NON-STEROIDAL COMPOUNDS WHICH ARE HIGH AFFINITY, HIGH SELECTIVITY MODULATORS FOR STEROID RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-09-19 | — | — | US | disclosed |
| US-6093821-A | MAKING 6-(PHENYL OR HETEROARYL)-1,2-DIHYDRO-N-1-PROTECTED QUINOLINE BY REACTING THE CORRESPONDING 6-HALO-DERIVATIVE WITH AN ORGANOBORATE AND ACID TREATMENT TO FORM THE 6-BORO-DERIVATIVE, COUPLING WITH PHENYL OR HETEROARYL HALIDE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-25 | — | — | US | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| CN-1175247-A | Steroid receptor modulator compounds and methods | LIGAND PHARM INC (US) | 1998-03-04 | — | — | CN | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | PGR 29/4885AR 7/4885KDM4E 3167/4885 |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | PGR 44/4885AR 1/4885KDM4E 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.